Dávid Németh

Dávid Németh

Auto-generated profile, based on publicly available information

Dávid Németh

Institute for Translational Medicine, University of Pécs Medical School, Pécs, Hungary

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
DND. Nemeth
D. Nemeth
LZL. Zaleczna
L. Zaleczna
AHA. Huremovic
A. Huremovic
JEJ. Engelmann
J. Engelmann
PPP.W. Poeschl
P.W. Poeschl
CPChristos Perisanidis
Christos Perisanidis

22 June 2020 in Maternal & Child Nutrition
Verified
Journal Article
Open access
PDF file
SESzimonetta Eitmann
Szimonetta Eitmann
DNDávid Németh
Dávid Németh
Peter HegyiPeter Hegyi
Peter Hegyi
ZSZsolt Szakács
Zsolt Szakács
Andras GaramiAndras Garami
Andras Garami
EPErika Pétervári
Erika Pétervári
This systematic review and meta‐analysis aimed to investigate the association between maternal overnutrition and offspring's insulin sensitivity—following the Preferred Reporting Items for Systematic Reviews and Meta‐analyses statement. Studies published in English before April 22, 2019, were identified through searches of four medical databases. After selection, 15 studies aiming to explore the association between prepregnancy body mass index (ppBMI) or gestational weight gain (GWG) of non‐diabetic mothers and their offspring's insulin sensitivity (fasting insulin or glucose level and Homeostatic Measurement Assessment for Insulin Resistance [HOMA‐IR]) were included in the meta‐analysis. Associations of ppBMI and GWG with offspring's insulin sensitivity were analysed by pooling regression coefficients or standardized differences in means with 95% confidence intervals (CIs). Maternal ppBMI showed significant positive correlations with the level of both fasting insulin and HOMA‐IR in offspring (standardized regression coefficient for fasting insulin: 0.107, CI [0.053, 0.160], p < 0.001 and that for HOMA‐IR: 0.063, CI [0.006, 0.121], p = 0.031). However, the result of the analysis on coefficients adjusted for offspring's actual anthropometry (BMI and adiposity) was not significant. Independent from ppBMI, GWG tended to show a positive correlation with insulin level, but not after adjustment for offspring's anthropometry. Offspring of mothers with excessive GWG showed significantly higher HOMA‐IR than those of mothers with optimal GWG (p = 0.004). Our results demonstrate that both higher ppBMI and GWG increase the risk of offspring's insulin resistance, but the effect of ppBMI on insulin sensitivity in offspring may develop as consequence of their adiposity.

19 May 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
SKSzabolcs Kiss
Szabolcs Kiss
DNDávid Németh
Dávid Németh
Peter HegyiPeter Hegyi
Peter Hegyi
MFMária Földi
Mária Földi
ZSZsolt Szakács
Zsolt Szakács
HAHussain Alizadeh
Hussain Alizadeh
Objective: The goal of treatment in ulcerative colitis (UC) is to induce and maintain remission. The addition of granulocyte and monocyte apheresis (GMA) to conventional therapy may be a promising therapeutic alternative. In this meta-analysis, we aimed to assess the efficacy and safety profile of GMA as an adjunctive therapy. Design: Systematic review and meta-analysis. Methods: We searched four databases (MEDLINE, Embase, Web of Science and Cochrane Central Register of Controlled Trials) for randomised or minimised controlled trials which discussed the impact of additional GMA therapy on clinical remission induction and clinical remission maintenance compared with conventional therapy alone. Primary outcomes were clinical remission induction and maintenance, secondary outcomes were adverse events (AEs) and steroid-sparing effect. ORs with 95% CIs were calculated. Trial Sequential Analyses were performed to adjusts for the risk of random errors in meta-analyses. Results: A total of 11 studies were eligible for meta-analysis. GMA was clearly demonstrated to induce and maintain clinical remission more effectively than conventional therapy alone (598 patients: OR: 1.93, 95% CI 1.28 to 2.91, p=0.002, I 2 =0.0% for induction; 71 patients: OR: 8.34, 95% CI 2.64 to 26.32, p<0.001, I 2 =0.0% for maintenance). There was no statistically significant difference in the number of AEs (OR: 0.27, 95% CI 0.05 to 1.50, p=0.135, I 2 =84.2%). Conclusion: GMA appears to be more effective as an adjunctive treatment in inducing and maintaining remission in patients with UC than conventional therapy alone. PROSPERO registration number: CRD42019134050.